newsfilter
← Latest News
GlobeNewswire·

Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference in London

  • Metagenomi Therapeutics, Inc. (Nasdaq: MGX) announced that President & CEO Jian Irish, Ph.D., M.B.A., will participate in a fireside chat at the Jefferies Global Healthcare Conference in London, UK.
  • The event is scheduled for Wednesday, November 18, 2026, at 12:00 p.m. ET.
  • A live webcast of the conference will be available on the Company's investor relations website.
  • Metagenomi is an in vivo genome editing company focused on creating curative genetic medicines using proprietary CRISPR tools.
  • The Company's lead program, MGX-001, is a one-time treatment for hemophilia A designed to provide durable, life-long protection from bleeding events.
  • Metagenomi is also pursuing additional indications leveraging its MGX-001 integration system & partnering on assets targeting cardiometabolic diseases.
  • Investor inquiries can be directed to Brian Ritchie at LifeSci Advisors.
Company
Metagenomi Therapeutics, Inc.
Keywords
Nasdaq:MGX, Metagenomi Therapeutics, Inc.